Strategic Asset Sale Consider outreach to AstraZeneca leveraging the recent asset sale to explore potential licensing, collaboration, or divestment opportunities that could unlock remaining therapeutic assets or technologies complementary to Achilles' AI-powered precision T cell platform.

AI Platform Value Position to collaborators and sponsors the PELEUS AI-driven bioinformatics platform for identification of clonal neoantigens, offering partnership models such as co-development, data licensing, or bespoke computational biology services to accelerate partner programs.

mRNA Collaboration Explore co-development or procurement opportunities with Arcturus Therapeutics or other mRNA vaccine players for complementary sa-mRNA personalized vaccines, enabling combined therapeutic strategies or shared translational capabilities.

Clinical Progress Leverage Phase I/IIa data and ongoing CHIRON THETIS trials to engage potential sponsors or pharma companies seeking to bolster solid-tumor immunotherapy pipelines with clonal neoantigen targets and T cell–based approaches.

Strategic Funding Highlight the company’s recent fundraising and modest revenue as a basis for co-investment discussions, investor-led partnerships, or milestone-driven collaborations that de-risk early-stage opportunities in AI-powered immunotherapies.